Tremelimumab.

Associated clinical trials:

Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma | NCT01008358

Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma | NCT00471887

A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued. | NCT00378482

CP-675,206 In Patients With Advanced Melanoma | NCT00086489

Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment | NCT00313794

CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer | NCT00702923

Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma | NCT00610857

Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC) | NCT00312975

A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer | NCT00556023

Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer | NCT00880854

Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma | NCT00372853

Study of CP-675,206 in Refractory Melanoma | NCT00254579

CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer | NCT00075192